Gavin Wood - 12 Jan 2022 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Role
Chief Financial Officer
Signature
/s/ Gavin Wood
Issuer symbol
ADAP
Transactions as of
12 Jan 2022
Net transactions value
$0
Form type
4
Filing time
13 Jan 2022, 20:03:03 UTC
Next filing
23 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADAP Option to purchase Ordinary Shares Award $0 +1,407,072 $0.000000 1,407,072 12 Jan 2022 Ordinary Shares 1,407,072 $0.6000 Direct F1, F2
transaction ADAP Option to purchase Ordinary Shares Award $0 +314,256 $0.000000 314,256 12 Jan 2022 Ordinary Shares 314,256 $0.001400 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from GBP0.44 based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2 Exercisable as to 351,768 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 29,454 Ordinary Shares on January 12, 2026.
F3 The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4 Exercisable as to 78,564 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.